| | | | | | | | The widely covered Legionnaires' disease outbreak brought national attention to the role of bioaerosol exposure in spreading infectious diseases. Now, in the absence of regulations specific to managing bioaerosol risks, pharma manufacturers need to find their own solutions. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | If your facility uses equipment like tablet presses, tablet coating, and fluid beds, it’s crucial to have dust collectors built specifically for pharmaceutical applications. The Gold Series Camtain® was designed to safeguard workers and facilities from potent compounds and other hazardous and explosive dusts. |
|
|
|
| |
| | |
|
|
| | | | | AstraZeneca now has a total equity stake of 44% in French-biotech Cellectis and the option to license up to 10 novel cell and gene therapy products. |
|
|
| Uproleselan, a potential a first-in-class e-selectin antagonist, did not achieve a statistically significant improvement in overall survival. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | Upholding rigorous quality standards is not only a regulatory imperative but also vital for ensuring the efficacy and safety of pharmaceutical products. And as many pharma manufacturers have discovered, enhanced quality processes can also unlock significant performance improvements.But quality improvements... |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
